Health Care & Life Sciences » Pharmaceuticals | China Medical System Holdings Ltd.

China Medical System Holdings Ltd. | Cash Flow

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
859
1,422
1,313
1,753
2,085
2,376
Depreciation, Depletion & Amortization
46
53
96
205
226
236
Other Funds
-
14
-
-
1,237
107
Funds from Operations
876
1,147
1,272
1,874
2,178
2,505
Changes in Working Capital
410
43
523
656
154
447
Net Operating Cash Flow
466
1,103
749
1,219
2,332
2,058
Capital Expenditures
171
329
716
1,236
88
Sale of Fixed Assets & Businesses
2
15
-
2
1
Purchase/Sale of Investments
-
1,182
344
472
356
Net Investing Cash Flow
267
1,234
1,333
1,725
443
Cash Dividends Paid - Total
302
366
456
541
705
Issuance/Reduction of Debt, Net
129
205
79
1,340
483
Net Financing Cash Flow
431
176
303
799
1,459
Net Change in Cash
210
308
276
296
430
Free Cash Flow
295
1,026
696
1,162
2,244
Net Assets from Acquisitions
100
-
283
-
-
Other Sources
577
638
11
-
-
Change in Capital Stock
-
-
837
-
-
Exchange Rate Effect
22
2
5
3
1
Other Uses
575
376
-
19
-

About China Medical System Holdings

View Profile
Address
6/F-8/F, Block B
Shenzhen Guangdong 518052
China
Employees -
Website http://www.cms.net.cn
Updated 07/08/2019
China Medical System Holdings Ltd. engages in the provision of pharmaceutical products and services. The company focuses on the manufacture, marketing, promotion, and sale of drugs. Its products include Plendi, XinHuoSu, Stulln, XiDaKang, YiNuoShu, DanShenTong, Hirudoid, NuoDiKang, Combizym, GanFuLe, Imdur, Parlodel, Lamisil, YinLianQingGan, and MOVICOL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.